재발성/불응성 비호지킨 림프종에서의 TORL-5-700 임상 연구
재발성 또는 난치성 비호지킨 림프종 환자를 대상으로 TORL-5-700 단독요법 및 병용요법에 대한 1/2상, 최초 인체 적용, 개방형, 다기관 연구
A Phase 1/2 study to evaluate safety, tolerability, and anticancer activity of TORL-5-700 as a monotherapy and in combination in R/R NHL
연구 개요
상태
상태
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
등록 (추정된)
등록
단계
단계
- 2 단계
- 1단계
연락처 및 위치
연구 연락처
연구 연락처
- 이름: Eric Park, M.D.
- 전화번호: (310) 598-5969
- 이메일: eric.park@torlbio.com
연구 장소
-
-
California
-
Fullerton, California, 미국, 92835
- 모병
- Providence Medical Foundation
-
Los Alamitos, California, 미국, 90720
- 모병
- Cancer and Blood Specialty Clinic, Los Alamitos
-
Santa Monica, California, 미국, 90404
- 모병
- UCLA
-
Stanford, California, 미국, 94305
- 모병
- Stanford University
-
-
Florida
-
Miami, Florida, 미국, 33136
- 모병
- University of California Miami, Sylvester Comprehensive Cancer Center
-
-
Iowa
-
Iowa City, Iowa, 미국, 52242
- 모병
- University of Iowa Health Care
-
-
Kansas
-
Wichita, Kansas, 미국, 67214
- 모병
- Cancer Center of Kansas, Wichita
-
-
Tennessee
-
Nashville, Tennessee, 미국, 37203
- 모병
- Sarah Cannon Research Institute
-
-
Texas
-
Dallas, Texas, 미국, 75390
- 모병
- University of Texas Southwestern Medical Center
-
-
참여기준
자격 기준
자격 기준
공부할 수 있는 나이
건강한 자원 봉사자를 받아들입니다
연구 대상 성별
설명
Inclusion Criteria:
- Confirmed B-NHL, including but not limited to de novo DLBCL; FL, Grades 1 to 3A; MCL; transformed lymphoma (tFL, RT) and FL Grade 3B; MZL and MALT.
- Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2.
- At least 1 measurable lesion per Lugano criteria.
- Tumor tissue is available.
- Adequate organ function
Exclusion Criteria:
- T-cell lymphoma
- CLL or SL
- Burkitt lymphoma and high-grade B-cell lymphoma
- CNS involvement
- Peripheral neuropathy > Grade 2
- Uncontrolled medical conditions
- Viral infections
공부 계획
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 무작위화되지 않음
- 중재 모델: 순차적 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Part 1: Monotherapy Dose Escalation
TORL-5-700 Administered once every three weeks |
Part 1: Monotherapy Dose Escalation - TORL-5-700 Administered once every three weeks |
|
실험적: Part 2: Monotherapy Expansion
TORL-5-700 at MTD/RP2D Administered once every three weeks |
Part 2: Monotherapy Expansion - TORL-5-700 at Maximum tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) Administered once every three weeks |
|
실험적: Part 3: Combination Evaluation
TORL-5-700 at MTD/RP2D Administered once every three weeks in combination with another agent |
Part 3: Combination Evaluation - TORL-5-700 at MTD/RP2D administered every three weeks in combination with another agent |
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Evaluate the safety of TORL-5-700 as a monotherapy
기간: though study completion, an average of 2.5 years
|
Assessment of adverse events according to NCI-CTCAE Version 5.0 |
though study completion, an average of 2.5 years
|
|
Assess the antitumor activity of TORL-5-700 as monotherapy
기간: though study completion, an average of 2.5 years
|
Assess the antitumor activity of TORL-5-700 using Cheson (2014) disease grading criteria |
though study completion, an average of 2.5 years
|
|
Evaluate the safety of TORL-5-700 in combination with other agents
기간: though study completion, an average of 2.5 years
|
Assessment of adverse events according to NCI-CTCAE Version 5.0 |
though study completion, an average of 2.5 years
|
|
Determine the Maximum Tolerated Dose (MTD)
기간: 21 days from the start of treatment
|
Determine the MTD by assessing Protocol defined Dose Limiting Toxicities (DLT) |
21 days from the start of treatment
|
|
Determine the Recommended Phase 2 Dose (RP2D)
기간: 21 days from the start of treatment
|
Determine the RP2D by assessing Protocol defined Dose Limiting Toxicities |
21 days from the start of treatment
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Maximum Serum Concentration of TORL-5-700 (Cmax)
기간: though end of study treatment, an average of 5 months
|
Pk assessment |
though end of study treatment, an average of 5 months
|
|
Maximum Serum Concentration of TORL-5-700 (Cmax) in combination with other agents
기간: though end of study treatment, an average of 5 months
|
Pk assessment |
though end of study treatment, an average of 5 months
|
|
Terminal Half-life (t1/2) of Serum TORL-5-700
기간: though end of study treatment, an average of 5 months
|
Pk assessment |
though end of study treatment, an average of 5 months
|
|
Terminal Half-life (t1/2) of Serum TORL-5-700 in combination with other agents
기간: though end of study treatment, an average of 5 months
|
Pk assessment |
though end of study treatment, an average of 5 months
|
|
Area under the Serum Concentration -Time curve for TORL-5-700 from the time of dosing to the last measurable concentration
기간: though end of study treatment, an average of 5 months
|
Pk assessment |
though end of study treatment, an average of 5 months
|
|
Area under the Serum Concentration -Time curve for TORL-5-700 from the time of dosing to the last measurable concentration in combination with other agents
기간: though end of study treatment, an average of 5 months
|
Pk assessment |
though end of study treatment, an average of 5 months
|
|
Clearance (CL) of TORL-5-700
기간: though end of study treatment, an average of 5 months
|
Pk assessment |
though end of study treatment, an average of 5 months
|
|
Clearance (CL) of TORL-5-700 in combination with other agents
기간: though end of study treatment, an average of 5 months
|
Pk assessment |
though end of study treatment, an average of 5 months
|
|
Volume of distribution of TORL-5-700
기간: though end of study treatment, an average of 5 months
|
PK assessment |
though end of study treatment, an average of 5 months
|
|
Volume of distribution of TORL-5-700 in combination with other agents
기간: though end of study treatment, an average of 5 months
|
PK assessment |
though end of study treatment, an average of 5 months
|
|
Immunogenicity of TORL-5-700
기간: though end of study treatment, an average of 5 months
|
Immunogenicity will be measured by incidence of treatment emergent ADAs |
though end of study treatment, an average of 5 months
|
|
Immunogenicity of TORL-5-700 in combination with other agents
기간: though end of study treatment, an average of 5 months
|
Immunogenicity will be measured by incidence of treatment emergent ADAs |
though end of study treatment, an average of 5 months
|
|
Assess the preliminary antitumor activity of TORL-5-700 in combination with other agents
기간: though study completion, an average of 2.5 years
|
Assess the antitumor activity of TORL-5-700 in combination with other agents using Cheson (2014) disease grading criteria |
though study completion, an average of 2.5 years
|
공동 작업자 및 조사자
연구 기록 날짜
연구 주요 날짜
연구 시작 (실제)
연구 시작
기본 완료 (추정된)
기본 완료
연구 완료 (추정된)
연구 완료
연구 등록 날짜
최초 제출
최초 제출
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
처음 게시됨 (실제)
처음 게시됨
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
마지막으로 확인됨
마지막으로 확인됨
추가 정보
이 연구와 관련된 용어
기타 연구 ID 번호
기타 연구 ID 번호
- TORL5700-001
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
미국 FDA 규제 기기 제품 연구
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .